These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 17096589

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure.
    Urai M, Kaneko Y, Ueno K, Okubo Y, Aizawa T, Fukazawa H, Sugita T, Ohno H, Shibuya K, Kinjo Y, Miyazaki Y.
    Front Cell Infect Microbiol; 2015; 5():101. PubMed ID: 26779451
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Regulated Release of Cryptococcal Polysaccharide Drives Virulence and Suppresses Immune Cell Infiltration into the Central Nervous System.
    Denham ST, Verma S, Reynolds RC, Worne CL, Daugherty JM, Lane TE, Brown JCS.
    Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29203547
    [Abstract] [Full Text] [Related]

  • 7. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
    Probert M, Zhou X, Goodall M, Johnston SA, Bielska E, Ballou ER, May RC.
    Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
    [Abstract] [Full Text] [Related]

  • 8. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.
    Chang ZL, Netski D, Thorkildson P, Kozel TR.
    Infect Immun; 2006 Jan; 74(1):144-51. PubMed ID: 16368967
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
    Beenhouwer DO, May RJ, Valadon P, Scharff MD.
    J Immunol; 2002 Dec 15; 169(12):6992-9. PubMed ID: 12471134
    [Abstract] [Full Text] [Related]

  • 11. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
    Fleuridor R, Lees A, Pirofski L.
    J Immunol; 2001 Jan 15; 166(2):1087-96. PubMed ID: 11145689
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
    Zhang H, Zhong Z, Pirofski LA.
    Infect Immun; 1997 Apr 15; 65(4):1158-64. PubMed ID: 9119446
    [Abstract] [Full Text] [Related]

  • 18. Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.
    Blackstock R.
    Immunology; 2003 Feb 15; 108(2):158-66. PubMed ID: 12562324
    [Abstract] [Full Text] [Related]

  • 19. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.
    Grinsell M, Weinhold LC, Cutler JE, Han Y, Kozel TR.
    J Infect Dis; 2001 Aug 15; 184(4):479-87. PubMed ID: 11471106
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.